<DOC>
	<DOCNO>NCT00709917</DOCNO>
	<brief_summary>This study conduct Europe . The aim observational study investigate switch metformin alone metformin combine repaglinide type 2 diabetic patient achieve adequate glycaemic control maximal dose metformin give alone analyse different epidemiological parameter .</brief_summary>
	<brief_title>Observational Study Switch Metformin Alone Metformin Combined With Repaglinide Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetic patient inadequate glycaemic control receive metformin alone maximal dose Signed informed consent Treatment accordance summary product characterisation Any contraindication metformin repaglinide</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>